uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

Launched by UROGEN PHARMA LTD. · May 22, 2023

Keywords

ClinConnect Summary

The uTRACT Jelmyto Registry is a clinical study designed to gather information about patients with Upper Tract Urothelial Cancer (UTUC) who are being treated with a medication called Jelmyto. This registry aims to understand how well Jelmyto works in real-life situations and how it affects patients' health outcomes. It is currently recruiting patients in the United States, and anyone aged 65 and older diagnosed with UTUC may be eligible to participate, especially if they have been treated with Jelmyto since April 2020, are currently receiving it, or are planned to start treatment soon.

Participants in this study will have the opportunity to share their experiences and health results while being treated with Jelmyto, helping doctors learn more about this treatment. There are no specific exclusions, so if someone meets the age and diagnosis criteria, they can take part. This is an important step in improving our understanding of UTUC and could help future patients with similar conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults \>18 years old and capable of giving informed consent.
• • Diagnosis of UTUC.
• • Receipt of at least 1 dose of JELMYTO after FDA approval (15 Apr 2020).
• Exclusion Criteria:
• • Incapable of giving informed consent (e.g., incarcerated individuals, individuals with dementia).
• • Receipt of 1 or more doses of JELMYTO (also referred to as UGN-101 or Mitogel in clinical development) before FDA approval (on or before 15 Apr 2020).
• • Pregnancy or lactation.
• • Unable to comply with protocol requirements (for prospective data capture).
• • Any medical or mental condition(s) that makes participation in the Registry inadvisable in the opinion of the Investigator (for prospective data capture).